1.-28. (Cancelled)

29. (Currently Amended) A tissue adhesive comprising fibrinogen and an admixed elastase inhibitor, wherein said elastase inhibitor is selected from the group consisting of eglin, α1-antiprotease, and mixtures thereof.

30.-32 (Cancelled)

33. (Original) A tissue adhesive as set forth in claim 29, wherein said tissue adhesive is comprised of human proteins.

34. (Withdrawn)

35. (Withdrawn)

36. (Previously Presented) A tissue adhesive as set forth in claim 29, wherein the ratio in weight of said elastase inhibitor to said fibrinogen is from 1:100 to 1:150,000.

37. (Previously Presented) A tissue adhesive as set forth in claim 29, wherein the ratio in weight of said elastase inhibitor to said fibrinogen is from 1:500 to 1:110,000.

38. (Original) A tissue adhesive as set forth in claim 29, wherein said tissue adhesive contains at least 10^{-6} U of elastase inhibitor per gram of fibrinogen.

39. (Original) A tissue adhesive as set forth in claim 29, wherein said tissue adhesive contains from between 10^{-3} and 10 U of elastase inhibitor per gram of fibrinogen.

40. (Original) A tissue adhesive as set forth in claim 29, further comprising plasminogen in an amount of at least 0.0001 mg/mg of fibrinogen.

41. (Original) A tissue adhesive as set forth in claim 40, wherein said plasminogen is contained in an amount of at least 0.001 mg/mg of fibrinogen.

42. (Original) A tissue adhesive as set forth in claim 40, wherein said plasminogen is contained in an amount of more than 0.01 mg/mg of fibrinogen.

43.-50 (Cancelled)

51. (Original) A tissue adhesive as set forth in claim 29, wherein said tissue adhesive is free from kininogenic proteins.

52. (Cancelled)

53. (Cancelled)

54. (Original) A tissue adhesive as set forth in claim 29, wherein said tissue adhesive is resistant to lysis in an environment with high activity for a period of time which is at least 10 hours.

55. (Original) A tissue adhesive as set forth in claim 29, wherein said tissue adhesive is resistant to lysis in an environment with high fibrinolytic activity for a period of time which is at least 15 hours.

56. (Original) A tissue adhesive as set forth in claim 29, wherein said tissue adhesive is lyophilized.

57. (Original) A tissue adhesive as set forth in claim 29, wherein said tissue adhesive is present in solution.

58. (Original) A tissue adhesive as set forth in claim 57, wherein said solution is deep-frozen.

59. (Original) A tissue adhesive as set forth in claim 29, wherein said tissue adhesive is present in virus-inactivated form.

60. (Original) A tissue adhesive as set forth in claim 29, wherein said elastase inhibitor is of recombinant origin.

61.-69 (Cancelled)

70. (Currently Amended) A method for treating wounds or hemorrhages with high fibrinolytic activity in patients, comprising administering an effective dose of a tissue adhesive preparation containing fibrinogen and an elastase inhibitor, wherein said elastase inhibitor is selected from the group consisting of eglin, α1-antiprotease, and mixtures thereof.

71. (Original) A method as set forth in claim 70, wherein said wound or hemorrhage is urological.

72. (Original) A method for treating wounds or hemorrhages in patients, comprising administering an effective dose of a tissue adhesive containing fibrinogen and an elastase inhibitor by means of an application device.

73. (Original) A method as set forth in claim 72, wherein said wound or hemorrhage is urological.